Background
Venous thromboembolism (VTE) is a major patient safety issue. The PSF-sponsored Venous Thromboembolism Prevention Study (VTEPS) examined whether post-operative enoxaparin prevents symptomatic VTE in plastic surgery patients.
Methods
VTEPS eligibility criteria included age ≥18, general anesthesia, and post-operative hospital admission. In 2009, four sites uniformly adopted a clinical protocol. Patients with Caprini score ≥3 received post-operative enoxaparin prophylaxis starting 6–8 hours after surgery and continuing for the duration of their inpatient stay. VTEPS historic control patients had an operation between 2006 and 2008 but received no chemoprophylaxis for 60 days after surgery. The primary study outcome was symptomatic 60-day VTE. Stratified analyses were performed. Multivariable logistic regression controlled for baseline risk and other identified confounders.
Results
3334 patients (1876 controls and 1458 enoxaparin patients) were included. Notable risk reduction was present in patients with Caprini >8 (8.54% vs. 4.07%, p=0.182) and Caprini 7–8 (2.55% vs. 1.15%, p=0.230) who received post-operative enoxaparin. Logistic regression was limited to highest risk patients (Caprini ≥7) and demonstrated that length of stay (LOS) ≥4 days (adjusted odds ratio (OR) 4.63, p=0.007) and Caprini score >8 (OR 2.71, p=0.027) were independent predictors of VTE. When controlling for LOS and Caprini score, receipt of post-operative enoxaparin was protective against VTE (OR 0.39, p=0.042).
Conclusions
In high-risk plastic surgery patients, post-operative enoxaparin prophylaxis is protective against 60-day VTE when controlling for baseline risk and LOS. Hospitalization ≥4 days is an independent risk factor for VTE.
Clinical Question
Risk
Level of Evidence
III (retrospective cohort study)